All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML

March 29th 2024

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.

Rezatapopt Revolutionizes Research Directions in TP53-Mutated Solid Tumors

March 29th 2024

Shivaani Kummar, MBBS, FACP, discusses the mechanism of action of the TP53-directed agent rezatapopt and efficacy data with this agent in solid tumors.

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Zamarin Shares Updates and Ongoing Research Endeavors in Gynecologic Oncology

March 29th 2024

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

Unpacking the Role of Cannabis in Oncology as Reclassification of the Drug Pends

March 29th 2024

Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.

FDA Grants Rare Pediatric Disease Designation to LSTA1 in Osteosarcoma

March 29th 2024

LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.

Targeted Treatment of Rare Childhood Leukemia

March 29th 2024

UCSF researcher to lead multicenter precision medicine trial for juvenile myelomonocytic leukemia.

All Eyes Are on IL-15 in Early Phase Studies

March 29th 2024

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Ponatinib Plus Chemo Records Several ‘Firsts’ in Ph+ ALL and Becomes New SOC

March 29th 2024

Elias Jabbour, MD, expands on the significance of ponatinib’s approval in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

March 28th 2024

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

China’s NMPA Accepts sBLA for Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

March 28th 2024

China’s NMPA accepted a sBLA for enfortumab vedotin plus pembrolizumab for the first-line treatment of locally advanced or metastatic urothelial cancer.

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Utah Legislature Allocates $75 Million to Vineyard Cancer Research Center

March 28th 2024

Huntsman Cancer Institute at the University of Utah received $75 million from the Utah Legislature toward a cancer research and academic building.

China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC

March 28th 2024

China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.

ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm

March 28th 2024

Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.

Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence

March 28th 2024

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

The Breast Cancer Index Impacts Physicians’ Decision to Extend Endocrine Therapy for HR+ Early-Stage Disease

March 28th 2024

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

March 27th 2024

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.